1. Home
  2. REE vs KALA Comparison

REE vs KALA Comparison

Compare REE & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo REE Automotive Ltd.

REE

REE Automotive Ltd.

HOLD

Current Price

$0.58

Market Cap

17.1M

ML Signal

HOLD

Logo KALA BIO Inc.

KALA

KALA BIO Inc.

HOLD

Current Price

$0.41

Market Cap

16.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REE
KALA
Founded
2011
2009
Country
Israel
United States
Employees
N/A
N/A
Industry
Auto Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.1M
16.1M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
REE
KALA
Price
$0.58
$0.41
Analyst Decision
Strong Buy
Buy
Analyst Count
2
3
Target Price
$11.75
$31.50
AVG Volume (30 Days)
107.2K
941.6K
Earning Date
03-16-2026
03-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$207,000.00
N/A
Revenue This Year
$327.73
N/A
Revenue Next Year
$36,888.82
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.53
$0.35
52 Week High
$8.38
$20.60

Technical Indicators

Market Signals
Indicator
REE
KALA
Relative Strength Index (RSI) 39.21 36.54
Support Level $0.54 $0.35
Resistance Level $0.60 $0.46
Average True Range (ATR) 0.05 0.05
MACD -0.00 -0.00
Stochastic Oscillator 35.09 24.11

Price Performance

Historical Comparison
REE
KALA

About REE REE Automotive Ltd.

REE Automotive Ltd is an automotive technology company focused on building commercial electric vehicles controlled fully by-wire. The company is in early stages of commercialization and develop and produce software-defined vehicle (SDV) technology that manages vehicle operations and features through proprietarily-developed software. The company has geographical preference in Israel, Germany, United States, United Kingdom, and other regions.

About KALA KALA BIO Inc.

Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Share on Social Networks: